Shear Kershman Labs, Texas A&M, and Innovative MedTech Partner to Revolutionize Oral Thrush Treatment
TL;DR
Collaboration between Shear Kershman Labs, Texas A&M College of Dentistry, and Innovative MedTech offers a strategic advantage in transformative healthcare initiatives.
The MOU aims to jointly design advanced technologies, enhance academic programs, and conduct collaborative research to drive medical and dental advancements.
The collaboration is poised to redefine the future of healthcare delivery, enhance patient care, and drive groundbreaking research for improved global patient outcomes.
BioViscid™, a bio-adhesive encapsulation for oral thrush, represents a pioneering technology in drug delivery with sustained release profiles over 6-8 hours post-application.
Found this article helpful?
Share it with your network and spread the knowledge!
Shear Kershman Laboratories, Texas A&M University College of Dentistry, and Innovative MedTech Inc. have signed a Memorandum of Understanding (MOU) to collaborate on advancing healthcare technologies, with a specific focus on developing a groundbreaking treatment for oral thrush.
The partnership centers on BioViscid™, a novel long-lasting formulation designed to provide highly effective bio-adhesion across mucosal tissues. Unlike existing treatments such as fluconazole or amphotericin B, BioViscid™ offers a unique approach by adhering directly to the mucosal cavity and avoiding first-pass metabolism.
The collaboration aims to address significant healthcare challenges, with oral candidiasis affecting approximately 5-7% of Americans. Particularly vulnerable populations include individuals with weakened immune systems, infants, elderly patients, and those with conditions like diabetes, HIV/AIDS, or cancer.
Key objectives of the partnership include jointly developing innovative solutions, advancing education and training, and promoting collaborative research. The bioequivalency study for oral thrush treatment represents a critical component of their joint efforts.
Early trials demonstrate BioViscid™ can maintain adherence and controlled release for 6-8 hours post-application, even in high-moisture environments. This breakthrough could potentially transform treatment approaches for oral thrush, which represents a global market estimated at $4-6 billion.
Dr. Blake Hawley from Shear Kershman Labs emphasized the formulation's potential to improve therapeutic outcomes, while Dr. Lily T. Garcia, Dean of Texas A&M College of Dentistry, highlighted the transformative potential of academic-industry collaboration.
The anticipated impact extends beyond oral thrush treatment, potentially introducing novel drug delivery methods, innovative solutions for underserved communities, and enhanced educational curriculum bridging technology and traditional medical practice.
Curated from NewMediaWire
